Sun Pharm acquires rights to trademarks of 3 diabetes drug brands in India from AstraZeneca

28 May 2021 Evaluate

Sun Pharma has acquired the rights to trademarks of diabetes drug Dapagliflozin under brands Oxra, Oxramet and Oxraduo in India from AstraZeneca AB, Sweden, parent company of AstraZeneca Pharma India with effect from May 28, 2021. The company has also taken a patent license to manufacture and commercialise Dapagliflozin and Dapagliflozin with Metformin combination in India from AstraZeneca AB with effect from May 28, 2021.

Consequently, AstraZeneca India and Sun Pharma have discontinued their existing distribution services agreement signed in 2016, for distribution of Dapagliflozin.

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1796.00 9.75 (0.55%)
11-Dec-2025 11:51 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1796.00
Dr. Reddys Lab 1268.20
Cipla 1501.55
Zydus Lifesciences 922.85
Lupin 2073.20
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×